Conference: 2014 International PHA Conference and Scientific Sessions
Release Date: 03.27.2017
Dunbar Ivy, M.D. Professor of Pediatrics
Selby's Chair in Pediatric Cardiology
Children's Hospital Colorado University of Colorado Hospital
To support the attainment of knowledge, competence, and performance, the learner should be able to achieve the following objectives:
Understand the difficulties in clinical trial design of PAH therapies in children
Evaluate the challenges and opportunities in performance of the sildenafil trial in children
Identify potential strategies in performance of future clinical trials in children
This educational activity is designed for;
Unapproved/Off-Label Use Disclosure
The faculty of this educational activity discloses the following to the participants:
When products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not US Food and Drug Administration [FDA] approved)
Any limitations on the information presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of FDA-approved labeling. This information is intended solely for educational purposes and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
Faculty, Planners, Staff Disclosure Information
All relevant financial relationships with any commercial interests and/or manufacturers must be disclosed to participants at the beginning of each activity. The faculty and planners of this educational activity disclose the following:
Dunbar Ivy, M.D., is or serves as Consultant/Advisory Board/Steering Committee with Acetelion Pharmaceuticals, Gilead Sciences, Inc, Pfizer, United Therapeutics, and Bayer Healthcare.
PHA and PESG Staff have no relevant financial relationships to disclose.